Dry Eye: Clinical Trials

60 trials for Dry Eye, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

60 completed. 60 Phase 2, 8 Phase 1, 6 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 260Completed 60
Phase 18Completed 8
Phase 36Completed 6

Follow Dry Eye: new trials by email Literature Review of Dry Eye trials Research Report on Dry Eye

Trials (filtered) newest first · largest first

All 60 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Preliminary Clinical Study of the Effectiveness and Safety of Ocular Surface Microbiota Transplantation in the Treatment of Dry Eye Disease
Ocular surface microbiota transplantation, placebo transplantation - Dry Eye
Phase 1 / Phase 2CompletedSecond Affiliated Hospital of Nanchang University302025-12-262026-10-16
Phase 2b Controlled Study of Dosing Techniques - Part B
IVW-1001 Ophthalmic Eyelid Wipe 0.2%, IVW-1001 Ophthalmic Eyelid Wipe 0.4% - Dry Eye
Phase 2CompletedIVIEW Therapeutics Inc.152025-09-082026-03-27
Comparing Efficacy of Tea Tree Oil Versus Topical Azithromycin in Treating Dry Eye
Tea Tree Oil Topical Application Oil, Azithromycin Ophthalmic Solution - Dry Eye
Phase 1 / Phase 2CompletedEhab Mohamed Elsayed Mohamed Saad502025-03-012026-09-30
Evaluation of BTV100 in Subjects With Dry Eye Disease
BTV100 Low dose, BTV100 Mid dose, BTV100 High dose - Dry Eye
Phase 2CompletedBioTheraVision, Inc.1232024-12-312026-10-07
A Study in the Treatment of Mild to Moderate Dry Eye Disease Comparing Saline to TTAX03.
TTAX03, Saline (NaCl 0,9 %) (placebo) - Dry Eye, Dry Eye Disease (DED)
Phase 2CompletedBioTissue Holdings, Inc742024-12-122026-02-11
Efficacy and Safety of Different Hyaluronic Acid Tear Substitutes Formulations in Evaporative Dry Eye
Icross tear substitute, Hyabak tear substitute - Dry Eye
Phase 2 / Phase 3CompletedUniversity of Seville302023-11-012024-07-26
Efficacy and Safety of a Multiple-Action Tear Substitute (TriMix) in Dry Eye Disease
Trimix tear substitutes, Hyaluronic acid tear substitute - Dry Eye
Phase 2 / Phase 3CompletedUniversity of Seville1242023-07-012024-06-27
Study of OT202 in Treating Moderate to Severe Dry Eye
OT202 conc 0.5%, OT202 conc 0.1%, Placebo - Dry Eye
Phase 2CompletedOcumension Therapeutics (Shanghai) Co., Ltd2132023-04-102024-05-30
Clinical Evaluation of a Multidose Preservative-free Lubricating Eye Drops Contained in Novelia® Eye Dropper in Non-Contact Lens Wearing Patients
Investigational Lubricating Eye Drop in a Novelia® bottle, Blink® Tears eye Drops - Dry Eye
Phase 2CompletedJohnson & Johnson Vision Care, Inc.1212023-02-232025-04-27
Efficacy of 0.38% and 0.18% Sodium Hyaluronate Ocular Lubricants for Dry Eye in Adult Gazan Participants
0.38% Sodium Hyaluronate (SH) Eye Drops, 0.18% Sodium Hyaluronate Eye Drops, Normal Saline Eye Drops - Dry Eye
Phase 2CompletedInternational Islamic University Malaysia452022-10-302025-03-03
Phase 2, Multi-center, Randomized, Double- Masked and Placebo-Controlled Study of YP-P10 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye (ICECAP 1)
0.3% YP-P10 Ophthalmic Solution, 1% YP-P10 Ophthalmic Solution, YP-P10 Placebo Ophthalmic Solution (vehicle) - Dry Eye
Phase 2CompletedYuyu Pharma, Inc.2572022-06-272024-07-30
Phase II Clinical Study to Evaluate the Efficacy of Multidose Lagricel® Ofteno Ophthalmic Solution as Treatment for Dry Eye Disease.
Sodium Hyaluronate Ophthalmic 0.4% one drop twice a day (BID), Sodium Hyaluronate Ophthalmic 0.4% one drop four times a day (QID), Sodium Hyaluronate Ophthalmic 0.4% Six times per day - Dry Eye
Phase 2CompletedLaboratorios Sophia S.A de C.V.1412022-01-032026-03-03
An Exploratory Crossover Clinical Trial to Compare the Activity of Reproxalap and Lifitegrast in a Dry Eye Disease Chamber
Reproxalap Ophthalmic Solution (0.25%), Xiidra® (5% lifitegrast ophthalmic solution) - Dry Eye
Phase 2CompletedAldeyra Therapeutics, Inc.562021-09-092025-02-28
A Clinical Trial to Assess Subjects With Dry Eye Disease.
Reproxalap Ophthalmic Solution (0.25%), Vehicle Ophthalmic Solution - Dry Eye
Phase 2CompletedAldeyra Therapeutics, Inc.1582021-06-152025-02-24
ALY688 Ophthalmic Solution in Subjects With Dry Eye Disease
ALY688 Ophthalmic Solution - Dry Eye
Phase 2 / Phase 3CompletedAllysta Pharmaceutical9222021-05-192023-03-16
To Assess the Efficacy and Safety of OTX-DED for the Short-term Treatment of Signs and Symptoms of Dry Eye Disease
OTX-DED - Dry Eye
Phase 2CompletedOcular Therapeutix, Inc.1722021-02-122023-02-22
Detection of Acetylsalicylic Acid and Omega-3 Fatty Acids in Schirmers' Test Strips Using Mass Spectrometry
Aspirin 500Mg Tab, Dr. Böhm® Omega 3 complex 870 mg - Dry Eye
Phase 2CompletedMedical University of Vienna322021-01-212023-03-20
Study of VVN001 Ophthalmic Solution in Dry Eye Disease
VVN001 Ophthalmic Solution 1%, VVN001 Ophthalmic Solution 5%, Vehicle - Dry Eye
Phase 2CompletedVivaVision Biotech, Inc1692020-12-032023-12-13
Clinical Trial to Compare the Safety and Efficacy of Nanodrop®
Nanodrop®, Systane Balance - Dry Eye
Phase 1 / Phase 2CompletedLaboratorios Sophia S.A de C.V.1262020-12-012025-07-16
The TRANQUILITY Trial: Clinical Trial to Assess the Efficacy and Safety in Subjects With Dry Eye Disease
Reproxalap Ophthalmic Solution (0.25%), Vehicle Opthalmic Solution - Dry Eye, Dry Eye Syndromes
Phase 2 / Phase 3CompletedAldeyra Therapeutics, Inc.3292020-11-212025-03-19

Showing 20 of 60. Sign in to see all of them.

Narrower conditions

Dry Eye Syndromes (60)  ·  Sjogren's Syndrome (3)  ·  Graft vs Host Disease (2)  ·  Keratoconjunctivitis Sicca (2)  ·  Xerophthalmia (2)  ·  Arthritis, Rheumatoid (1)  ·  Blepharitis (1)  ·  Keratitis (1)  ·  Lupus Erythematosus, Systemic (1)  ·  Meibomian Gland Dysfunction (1)  ·  Meibomitis (1)  ·  Scleroderma, Diffuse (1)

Broader conditions

Eye Diseases (60)  ·  Lacrimal Apparatus Diseases (60)  ·  Immune System Diseases (4)  ·  Arthritis (3)  ·  Autoimmune Diseases (3)  ·  Conjunctival Diseases (3)  ·  Connective Tissue Diseases (3)  ·  Joint Diseases (3)  ·  Mouth Diseases (3)  ·  Musculoskeletal Diseases (3)  ·  Rheumatic Diseases (3)  ·  Salivary Gland Diseases (3)  ·  Skin and Connective Tissue Diseases (3)  ·  Stomatognathic Diseases (3)  ·  Xerostomia (3)

Interventions

Carboxymethylcellulose Sodium (2)  ·  Doxycycline (2)  ·  Ophthalmic Solutions (2)  ·  lifitegrast (2)  ·  Aspirin (1)  ·  BID protein, human (1)  ·  Brimonidine Tartrate (1)  ·  Capsules (1)  ·  Cyclosporins (1)  ·  Dexamethasone (1)  ·  Glycerol (1)  ·  Hyaluronic Acid (1)  ·  Immunoglobulins, Intravenous (1)  ·  Loteprednol Etabonate (1)  ·  Nerve Growth Factor (1)

Sponsors

Aldeyra Therapeutics, Inc. (4)  ·  Santen Inc. (3)  ·  Alcon Research (2)  ·  Laboratorios Sophia S.A de C.V. (2)  ·  Novartis Pharmaceuticals (2)  ·  Ocular Therapeutix, Inc. (2)  ·  Silk Technologies, Ltd. (2)  ·  University of Seville (2)  ·  Abbott Medical Optics (1)  ·  Alacrity Biosciences, Inc. (1)  ·  Alcon, a Novartis Company (1)  ·  Allergan (1)  ·  Allysta Pharmaceutical (1)  ·  Aurinia Pharmaceuticals Inc. (1)  ·  AxeroVision, Inc. (1)

Countries

United States (38)  ·  China (4)  ·  Australia (2)  ·  Canada (2)  ·  Mexico (2)  ·  Spain (2)  ·  Austria (1)  ·  Chile (1)  ·  Egypt (1)  ·  Japan (1)  ·  New Zealand (1)  ·  Palestinian Territories (1)  ·  Taiwan (1)

Top investigators

Gail Torkildsen, MD (5)  ·  Anat Galor, MD, MSPH (1)  ·  Cristhian A Urzua, MD (1)  ·  Edmund K Waller, MD PhD (1)  ·  Eric Donnenfeld, M.D. (1)  ·  Eugene McLaurin, MD (1)  ·  Gail L Torkildson, MD (1)  ·  Giacomina Massaro Giordano, MD (1)  ·  Jamie Christensen (1)  ·  Jay H. Mashburn (1)  ·  Jialu Xia (1)  ·  Joel Naor, MD (1)  ·  John Lonsdale, MD (1)

Results publications

PMID 11879137, PMID 17508121, PMID 18848318, PMID 20735287, PMID 22330307, PMID 22670856, PMID 25826322, PMID 28777385, PMID 31373862, PMID 33096271, PMID 33561944, PMID 35192105, PMID 36586669, PMID 37077305, PMID 37209594, PMID 37478969, PMID 42764009, PMID 42803882, PMID 9894935